Search company, investor...

FIZE Medical

fizemedical.com

Founded Year

2014

Stage

Series A - II | Alive

Total Raised

$7.3M

Last Raised

$5.3M | 2 yrs ago

About FIZE Medical

FIZE Medical provides solutions for accurate, real-time monitoring or vital signs. Fize's solutions is a device that continuously monitors renal output.

Headquarters Location

Modi'in Technological Park HaHaruv St 1

Modi'In, 7177871,

Israel

+972-747323009

Compete with FIZE Medical?

Ensure that your company and products are accurately represented on our platform.

Expert Collections containing FIZE Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

FIZE Medical is included in 4 Expert Collections, including Health Monitoring & Diagnostics.

H

Health Monitoring & Diagnostics

2,530 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

M

Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,901 items

Latest FIZE Medical News

FIZE Medical Completes $5.3 Million Series A Financing

Apr 7, 2021

- Rapha Capital Management (RCM LLC) Joined by Mendham Investment Group (MIG FZ LLC) in Leading the Financing - FIZE's Novel iUO™ Device Conquers the Last Frontier in Patient Monitoring - Rapha Capital's Inaugural First Managed VC Fund, Rapha Capital BioVentures Fund I, also participated in the Series A financing MIAMI, April 6, 2021-- FIZE Medical, Inc. ("FIZE")(www.fizemedical.com) recently closed a Series A financing led by Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, through Rapha Capital Investment IX, LLC ("RCI IX") (an entity managed by Rapha Capital). RCI IX was joined in the lead by MIG FZ LLC, led by Michael Ingber MD, Director of The Center for Specialized Women's Health at Garden State Urology, within the Atlantic Health System. This second, final tranche of financing completes FIZE's Series A financing, initiated with the first tranche closing in May, 2020 (see press release). The total $5.3 million financing will be used to further develop and commercialize FIZE's novel device, the iUO™, the first accurate, automatic, digital, and cost-effective device to measure urine output in real time, replacing the current, manually managed, urinometer bag attached to a standard Foley catheter, to be made available to hospitals and physicians worldwide. Rapha Capital's inaugural first managed VC Fund, Rapha Capital BioVentures Fund I also participated in this financing. Rapha Capital Management is an investment management firm focused on managing strategic investments in early stage, non-public biotechnology companies, previously through special purpose investment vehicles ("SPIVs"). Rapha Capital was founded by its President, Kevin Slawin, M.D., a successful and experienced oncologic and robotic surgeon. After leaving practice, Dr. Slawin has been serving as a biotech consultant, investor, and founder, focusing on disruptive technologies in oncology, T cells and immunotherapy, and other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. ("Bellicum"), a publicly traded company listed on NASDAQ, leading Bellicum to a successful $161 million IPO in December, 2014. He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as a board member at 3DBio Therapeutics, Inc (https://3dbiocorp.com/), FIZE Medical, Inc. (www.fizemedical.com), and Demeetra AgBio, Inc. (www.demeetra.com). He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. (www.asclepix.com) in 2020, engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. Rapha Capital Management will be offering alternative asset management services to its inaugural venture capital fund, launching April 15th, 2021, which will be the vehicle for all future investments managed by Rapha Capital Management. "FIZE's basic device, the iUO™, by itself is a giant leap forward in medicine, conquering the last frontier in patient monitoring by digitizing urine output, measured in real time, and placing it at the physicians' fingertips." said Kevin Slawin MD. "FIZE's vision, to be delivered through its pipeline of follow-on products, the iUO PLUS ™, and iUO DUOFLO ™, is poised to truly transform medicine by adding acute kidney injury (AKI) and shock prediction, core temperature and intraabdominal pressure monitoring (IAP), fluid balance and diuretic use and monitoring, real time urinalysis and UTI management, and automated intravesical chemotherapy and continuous bladder irrigation (CBI) therapy to the iUO™'s core capabilities," he added. "It's been gratifying to see how Urologists, including our lead investors Drs. Slawin and Ingber, who understand better than most the optimal management of Foley catheters, respond with such excitement and commitment to our company's technology and the advances it offers to their patients," said Dror Zerem, CEO of FIZE Medical. The COVID 19 pandemic has led to a realization of the need to prioritize technologies that increase protection of healthcare workers, while improving the care of critically ill patients, and providing enhanced efficiency. The FIZE® iUO™ device addresses all of these goals by reducing the number of times a nurse/healthcare worker needs to enter the room of an infected patient by automating bladder management. About FIZE Medical – "Making Every Drop Count" - FIZE® Medical is developing a state-of-the-art platform of assays to measure key indicators of the health status of patients found in their urine, in real-time, delivered through FIZE®'s groundbreaking devices, the iUO ™, iUO PLUS ™, and iUO DUOFLO ™. The basic FIZE® device, iUO™, measures real time urine production in a fully automated fashion and integrated into current healthcare IT platforms like the EMR. FIZE®'s advanced line of products provides a comprehensive solution by extracting all additional clinically relevant information from the urine and providing it to clinicians at their fingertips. The FIZE® technology is poised to advance significantly the delivery of healthcare without the added burden of increasing cost. FIZE Medical is headquartered in Modi'in, Israel. For more information, visit www.fizemedical.com or email info@fizemedical.com. About Rapha Capital Management, LLC - Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on identifying and managing strategic investments in early stage, non-public biotechnology companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc., a publicly traded company listed on NASDAQ. He is co Inventor of the FDA,-approved "prostate health index (phi)" test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America's Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology. For more information about Rapha Capital Management, email info@raphacapital.com or visit https://www.raphacap.com

FIZE Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

FIZE Medical Rank

FIZE Medical Frequently Asked Questions (FAQ)

  • When was FIZE Medical founded?

    FIZE Medical was founded in 2014.

  • Where is FIZE Medical's headquarters?

    FIZE Medical's headquarters is located at Modi'in Technological Park, Modi'In.

  • What is FIZE Medical's latest funding round?

    FIZE Medical's latest funding round is Series A - II.

  • How much did FIZE Medical raise?

    FIZE Medical raised a total of $7.3M.

  • Who are the investors of FIZE Medical?

    Investors of FIZE Medical include Rapha Capital Management and MIG FZ.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.